Vericel Corporation (VCEL)

Market Cap	1.87B -36.6%
Revenue (ttm)	258.72M +14.1%
Net Income	13.08M +268.7%
EPS	0.25 +236.5%
Shares Out	50.57M
PE Ratio	149.54
Forward PE	70.99
Dividend	n/a
Ex-Dividend Date	n/a

Volume	470,872
Open	37.15
Previous Close	37.10
Day's Range	36.07 - 37.59
52-Week Range	29.24 - 63.00
Beta	1.23
Analysts	Strong Buy
Price Target	57.50 (+55.91%)
Earnings Date	Feb 26, 2026

About VCEL

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use devic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 4, 1997
• Employees: 357
• Stock Exchange: NASDAQ
• Ticker Symbol: VCEL
• Website: https://www.vcel.com

Analyst Summary

According to 5 analysts, the average rating for VCEL stock is "Strong Buy." The 12-month stock price target is $57.5, which is an increase of 55.91% from the latest price.

Price Target

$57.5

(55.91% upside)

Analyst Consensus: Strong Buy